HRMY Harmony Biosciences Holdings
Company Analysis
Latest News
🟢 Harmony Biosciences is trading 4.06% up today despite biotech stocks falling 4.24%
Harmony Biosciences is trading 4.06% up now at $40.98, despite broad market weakness and a 4.24% decline in biotechnology stocks. - No clear company-specific...
🔴 Harmony Biosciences is trading 4.1% down in pre-market today as biotech stocks retreat
Harmony Biosciences is trading 4.1% down now at $36.50, primarily amid a biotech-sector pullback following the Moderna-fueled rally. - The stock closed at...
🔴 Harmony Biosciences falls 4.2% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Harmony Biosciences Upgraded to Strong Buy, Following Record Q2 Earnings Beat
Wall Street Zen upgraded Harmony Biosciences to a strong-buy rating on August 16, 2026. The move follows the company’s record-breaking second-quarter financial...
Harmony Biosciences Posts a Blowout Quarter, But Can a One-Drug Company Justify Its Run Toward Billion-Dollar Revenue?
Shares of Harmony Biosciences surged 11.2% to $39.58 after the rare-disease drugmaker delivered a record second quarter that blew past Wall Street expectations...
🟢 Harmony Biosciences is trading 11.5% up today on record Q2 results and reaffirmed full-year guidance
Harmony Biosciences is trading 11.5% up at $39.58 after reporting record Q2 2026 results driven by strong demand for WAKIX. • Revenue for the quarter grew 30%...
Harmony Biosciences' second quarter revenue grew 30% to $261.3M, beating estimates while the company reiterates FY26 guidance.
Harmony Biosciences reported record second quarter 2026 net revenue of $261.3 million, a 30% increase year-over-year, driven by continued strong demand for...
🟢 Harmony Biosciences is trading 4.4% up today ahead of Q2 earnings report
Harmony Biosciences is trading at $37.17 (up 4.4%) in pre-market, extending its recent upward trend as investors position ahead of the company’s Q2 2026...
Harmony Biosciences Holdings Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
Harmony Biosciences is projected to report Q2 2026 revenue of $249.0 million and EPS of $0.97, with the stock’s current price of $35.24 trading well below the...
🔴 Harmony Biosciences is trading 5.3% down
Harmony Biosciences is trading at $34.90, down 5.3% from a comparison close of $36.84 during regular trading. This is a price-action follow-up, so a separate...
🟢 Harmony Biosciences is trading 4.01% up today after setting Q2 2026 earnings date
Harmony Biosciences is trading 4.01% up at $34.84 after the company announced it will report second quarter 2026 financial results on August 4, 2026. * The...
Harmony Biosciences preannounces record second quarter 2026 revenue of $261 million, reaffirming full-year guidance.
Harmony Biosciences preannounced preliminary second quarter 2026 net product revenue of approximately $261 million, a 30% increase year-over-year. The company...
🔴 Harmony Biosciences is trading 4.1% down today as investors weigh Wakix patent litigation risks
Harmony Biosciences is trading at $36.63 (4.1% down) amid ongoing volatility tied to Wakix patent litigation and shifting analyst views on long-term...
Harmony Biosciences Reaffirmed at Mizuho, Trial Review Supports Wakix Patent
Mizuho reiterated its Outperform rating and $50.00 price target for Harmony Biosciences. The firm issued the update after reviewing trial transcripts regarding...
🟢 HRMY is trading 4.5% up today as it tests resistance amid healthcare sector rotation
HRMY is trading at $38.66 (up 4.5%) as the stock maintains strong bullish momentum and technical strength. • The stock is currently testing a key resistance...